Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study

• Main Authors: A. Iurlo (Author), D. Cattaneo (Author), D. Consonni (Author), F. Castagnetti (Author), M. C. Miggiano (Author), G. Binotto (Author), M. Bonifacio (Author), G. Rege-Cambrin (Author), M. Tiribelli (Author), F. Lunghi (Author), A. Gozzini (Author), P. Pregno (Author), E. Abruzzese (Author), I. Capodanno (Author), C. Bucelli (Author), M. Pizzuti (Author), S. Artuso (Author), M. Iezza (Author), E. Scalzulli (Author), G. La Barba (Author), A. Maggi (Author), S. Russo (Author), C. Elena (Author), A. R. Scortechini (Author), A. Tafuri (Author), R. Latagliata (Author), G. Caocci (Author), M. Bocchia (Author), S. Galimberti (Author), L. Luciano (Author), C. Fava (Author), R. Foà (Author), G. Saglio (Author), G. Rosti (Author), M. Breccia (Author)
• Format: Bog
• Udgivet: Frontiers Media S.A., 2023-03-01T00:00:00Z.
• Fag: article
• Online adgang: Connect to this object online.

TKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevant morbidity and mortality. Consequently, TKIs dose reduction is often used to prevent AEs. However, data on its impact on successful treatment-free remission (TFR) are quite scarce. We conducted a ret...